0001477932-23-000656.txt : 20230131 0001477932-23-000656.hdr.sgml : 20230131 20230131171321 ACCESSION NUMBER: 0001477932-23-000656 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20230125 ITEM INFORMATION: Entry into a Material Definitive Agreement ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230131 DATE AS OF CHANGE: 20230131 FILER: COMPANY DATA: COMPANY CONFORMED NAME: United Health Products, Inc. CENTRAL INDEX KEY: 0001096938 STANDARD INDUSTRIAL CLASSIFICATION: ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUPPLIES [3842] IRS NUMBER: 841517723 STATE OF INCORPORATION: NV FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-27781 FILM NUMBER: 23573392 BUSINESS ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 BUSINESS PHONE: (877) 358-3444 MAIL ADDRESS: STREET 1: 10624 S. EASTERN AVE STREET 2: STE. A209 CITY: HENDERSON STATE: NV ZIP: 89052 FORMER COMPANY: FORMER CONFORMED NAME: United EcoEnergy Corp. DATE OF NAME CHANGE: 20060224 FORMER COMPANY: FORMER CONFORMED NAME: MNS EAGLE EQUITY GROUP III INC DATE OF NAME CHANGE: 19991019 8-K 1 ueec_8k.htm FORM 8-K ueec_8k.htm

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): January 25, 2023

 

UNITED HEALTH PRODUCTS, INC.

(Exact name of registrant as specified in its charter)

 

Nevada

 

000-27781

 

84-1517723

(State or other jurisdiction

of incorporation)

 

(Commission File Number)

 

(IRS Employer

Identification No.)

 

526 Commerce Circle, Suite 120

Mesquite, NV 89027

(Address of Principal Executive Offices) (Zip Code) 

 

(475) 755-1005

Registrant’s telephone number, including area code

 

______________________________________________________

(Former Name or Former Address, if Changed Since Last Report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

 

Emerging Growth Company ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading Symbol(s)

 

Name of each exchange on which registered

N/A

 

N/A

 

N/A

 

 

 

 

Item 1.01 Entry into a Material Definitive Agreement.

 

Amendment to the Common Stock Purchase Agreement dated September 1, 2022:

 

As previously reported by United Health Products, Inc. (the “Company”) in a Current Report on Form 8-K filed with the Securities and Exchange Commission on September 7, 2022, the Company previously entered into a common stock purchase agreement dated September 1, 2022 (the “CSPA”) with White Lion Capital, LLC (“White Lion”).

 

The CSPA originally provided the Company with the right, but not the obligation, to require White Lion to purchase shares of the Company’s common stock at a purchase price equal to 93% of the lower of (i) the volume-weighted average price (the “VWAP”) of the Company’s common stock during a period of five consecutive trading days following the Company’s exercise of its right to sell shares, or (ii) the closing price of its common stock on the day the Company exercises its right to sell shares, subject to a minimum price of $0.25 per share (the “Floor Price”). The CSPA also originally provided that the Company may not issue a share purchase notice to White Lion if the Company’s common stock is trading below the Floor Price unless White Lion waives the Floor Price condition at its discretion.

 

On January 25, 2023, the Company and White Lion amended the CSPA to provide that if the Company issues a share price purchase notice at a time that the Company’s common stock is trading below the Floor Price and White Lion waives the Floor Price condition, the share purchase price multiplier for that transaction will be 90% instead of 93%.

 

Except as set forth in the amendment to the CSPA, all other terms, conditions, and provisions of the CSPA, remain in full force and effect.

 

The foregoing summary of the material terms of the amendment to the CSPA are qualified entirely by reference to the full text of the amendment, a copy of which will be filed with the Company’s Annual Report on Form 10-K for the year ended December 31, 2022.

 

Item 8.01. Other Events. 

 

On January 31, 2023, the Company issued a press release announcing an update on the FDA’s Premarket Approval Application for the Company’s HemoStyp® Gauze and the amendment to the CSPA with White Lion.

 

A copy of the press release is attached as Exhibit 99.1 and is incorporated herein by reference.

 

Item 9.01. Financial Statements and Exhibits. 

 

(d) Exhibits

 

Exhibit Number

Description

 

 

 

99.1

 

Press release, dated January 31, 2023

104

 

Cover Page Interactive Data File (embedded within the Inline XBRL Document)

 

 
2

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

 

United Health Products, Inc.

 

 

Dated: January 31, 2023

By:

/s/ Brian Thom

 

Brian Thom

Chief Executive Officer

 

 
3

 

 EX-99.1 2 ueec_ex991.htm PRESS RELEASE ueec_ex991.htm

EXHIBIT 99.1

 

United Health Products Provides Update on FDA PMA Application and

Amendment to White Lion Agreement

 

Mesquite, Nevada – January 31, 2023 – United Health Products, Inc. (OTCPK: UEEC), (UHP) today provided an update on the company’s FDA Premarket Approval application process and the amendment of its Agreement with White Lion Capital.

 

UHP continues to advance its Premarket Approval application with the Food and Drug Administration. Last December, a batch lot of HemoStyp gauze produced under its new manufacturing arrangements was shown to have physical and chemical characteristics that were effectively identical to those of the HemoStyp product utilized in the company’s human trial. Subsequently, the company, in consultation with its regulatory consultant and reflecting feedback from the FDA, has produced additional batch lots of HemoStyp product to demonstrate consistent production, which the company believes is an important criterion for Premarket Approval. Samples of these additional lots are now undergoing similar laboratory testing procedures to confirm the consistency of the company’s manufacturing process, which results will be included in its final PMA application.

 

There can be no assurance that the company’s PMA application will be approved.

 

Separately, in September 2022 the company entered into a Common Stock Purchase Agreement with White Lion Capital, LLC under which the company has the right to sell shares of its common stock to White Lion at a price equal to 93% of the five-day volume weighted average trading price. The company has successfully raised over $350,000 to fund its operations under the Agreement. The Agreement contains a condition that the company share price must be above $0.25 per share (the Floor Price) in order to issue a share purchase notice, which White Lion can waive at its discretion. On January 25, 2023, the company and White Lion amended the Agreement such that if the company issues a purchase notice when its shares are trading below the Floor Price and White Lion waives the Floor Price condition, White Lion’s purchase price per share in that transaction will be 90% of the five-day volume weighted average trading price rather than 93%. All other terms of the Agreement remain unchanged.

 

About United Health Products-- UHP develops, manufactures and markets HemoStyp™, a patented Neutralized Oxidized Regenerated Cellulose (NORC) hemostatic agent. HemoStyp is an all-natural product designed to control bleeding. UHP currently offers a suite of hemostatic products to the dental, veterinary and emergency medicine markets, and is seeking approval to access the human surgical market.

 

For more information on UHP visit the company’s new website: www.uhpcorp.com or contact the company at info@uhpcorp.com.

 

The company can also be reached by phone or text message at 475.755.1005

 

Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release may contain forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements that include the words “believes,” “expects,” “anticipates” or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward-looking statements.

 EX-101.SCH 3 ueec-20230125.xsd XBRL TAXONOMY EXTENSION SCHEMA 000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ueec-20230125_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Entity Registrant Name Entity Central Index Key Document Type Amendment Flag Entity Emerging Growth Company Document Period End Date Entity Incorporation State Country Code Entity File Number Entity Tax Identification Number Entity Address Address Line 1 Entity Address Address Line 2 Entity Address City Or Town Entity Address State Or Province Entity Address Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer EX-101.CAL 5 ueec-20230125_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.PRE 6 ueec-20230125_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE EX-101.DEF 7 ueec-20230125_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.22.4
Cover
Jan. 25, 2023
Cover [Abstract]  
Entity Registrant Name UNITED HEALTH PRODUCTS, INC.
Entity Central Index Key 0001096938
Document Type 8-K
Amendment Flag false
Entity Emerging Growth Company false
Document Period End Date Jan. 25, 2023
Entity Incorporation State Country Code NV
Entity File Number 000-27781
Entity Tax Identification Number 84-1517723
Entity Address Address Line 1 526 Commerce Circle
Entity Address Address Line 2 Suite 120
Entity Address City Or Town Mesquite
Entity Address State Or Province NV
Entity Address Postal Zip Code 89027
City Area Code 475
Local Phone Number 755-1005
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
XML 9 ueec_8k_htm.xml IDEA: XBRL DOCUMENT 0001096938 2023-01-25 2023-01-25 iso4217:USD shares iso4217:USD shares 0001096938 false 8-K 2023-01-25 UNITED HEALTH PRODUCTS, INC. NV 000-27781 84-1517723 526 Commerce Circle Suite 120 Mesquite NV 89027 475 755-1005 false false false false false EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( *F)/U8'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " "IB3]6>4NS6^X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)OIVG00^CVLN))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RP(U&4 %D?T:E7Y9U*^LS M*:^Q_,I6TBGBAETFOXKM_>Z!]6W3BJKAE>"[MI5<2'[[/KO^\+L*NV#LWOYC MXXM@W\&ON^B_ %!+ P04 " "IB3]6F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M *F)/U:'5DH3[P, $,/ 8 >&PO=V]R:W-H965T&UL MC9==<]HX%(;_BL8[LU=-;)GO%)@A)-G0)H0)I)W9G;U0; &:VI(KB9#\^SVR MP:9=<^ &6[;/RR,=G5=2?ZOT#[/FW)+W-)%FX*VMS:Y\WT1KGC)SJ3(NX67*K%(N31"2:+Y[]7O M\LY#9UZ9X6.5?!>Q70^\KD=BOF2;Q#ZK[3W?=:CE]"*5F/R7;(MOFX%'HHVQ M*MT% T$J9'%E[[N!. @(>T<"PEU /A!^\4U3P: MX(1T69E;#6\%Q-GA6+UQW?^4HX0FG)E*6\CA+7>9E.%K+A>*VR[(H*RBF!:"!TE6%70ROGI M6=9?RQG64O# *.K#)^>Y?A[JK%K/&FR4%M9RX:K/7+ST^%A:)7I M4]RV?T,KZA789EJ]"1G5ENL)2;Q>JY6 XE;^&]E,&0NKY=\B.VHC)P2[O2#L M8&C5XD!Q-\\3.(+]]7$47*#9:6$@U6I <1-_4!&,R6RM).IIN$BGU;J@08 2 M58L Q14;+MCSP,;Z:;FLS]\)O9-D!_M[W)W_1S8Q9@-D M)P%QV:. _L&1R!TO'YG;;1F2\"4(!9<=,!I=G-B*AE59?DIZ51;.7/GM&DZY M7+L/X/U2*;MON(-7>6X>_@=02P,$% @ J8D_5I^@&_"Q @ X@P T M !X;"]S='EL97,N>&ULW5=M:]LP$/XK0C]@;F)JXI$8MD!AL(U"\V%?E5AV M!'KQ9+ES^NNGLVPG:75EW8>QS:')W3VZNT=W)YFN6W>2_.'(N2.]DKK=T*-S MS?LD:0]'KEC[SC1<>Z0R5C'G55LG;6,Y*UMP4C)9WMQDB6)"TV*M.W6G7$L. MIM-N0V]H4JPKH\^6E :#7\H4)X],;NB62;&W8EC+E)"G8%Z"X6"DL<1Y*GQ# M%V!IGP*\"!JP'.,HH8T%8Q(RA._]N/P9,&FM5X64,\$E#89BW3#GN-5W7AD6 M#\87$!GEW:GQ#&O+3HOE+3T[##\^R=[8DMLYS8).IF(M>05TK*B/\.M,DP#H MG%%>* 6KC68#A\EC%'S8 Y?R 5KXK;J*W5B'_2^FO-CT1=X=-8T\O1!BEHK M'O;^RPF+-9O\R-%8\>2SP:0)P:?EA6;/CO9NFJ:]PSLM_D/.? MK7/--;=,7I+VH_\W5_DMC)/Q]%PZC+N.HL?X;[:)'- MM[#/)73)>UYN1]76^T$D7O!9QP<&%Y_J?] MK-#]! SCMHHB*]1GA?H$KQBR'3Y8GKA/[I_X3O,\3;,,J^AV&V6PQ>J69? 7 MCX9Q P\L#V1Z6ZWQ;N,3\OH<8#U];4*PG>*3B.T4KS4@\;J!1Y['NXWE 0^L M"]CL0/YX'IBIN$^:0ERHY_U=3_ 102P,$% @ J8D_5I>* MNQS $P( L !?3T\$MP>:4#M.*2VBZD8_1!2:5K5N %( MMB6/:(7->=I3W;+T]! M;X"O.DQQ0FE(2S,.\,W2?S+W\PPU1>5*(Y5;&GC3Y?YVX$G1H2)8%II%R=.B M':5_'B4?'D78FYJD6:>IK&HP=MX1PT$G53$WHI"/J:Q8;!EK '$NW2:9;/46PQF MN1BUMIS> A(H!"DHV1%[A$O\G7D(GP&LK\,S4-AB.G8RF2&]B]#V,YU#BG/]3(U45%K"FHO409.B1 MP74&0ZRQB28)UD-N5G0&[O+H YMRR"9JZJ8IGJ,.>%,.]D9/)508H'Q3F:B\ M]E-L.>F.7F=Z_S!YU!Y:YU;*O8=7LN48Y0]02P,$% @ J8D_5B0> MFZ*M ^ $ !H !X;"]?+7_OR4Z?:!1W M;J"V\R1&:P;*9,OL[P"D6[2*+L[C,$]J%ZSB688&O-*]:A"2*+I!V#-DGNZ9 MHIP\_D-T==UI?#C]LCCP#S"\7>BI160I2A4:Y$S":+8VP5+BRTR6HJ@R&8HJ MEG!:(.+)(&UI5GVP3TZTYWD7-_=%KLWC":[?#'!X=/X!4$L#!!0 ( *F) M/U9ED'F2&0$ ,\# 3 6T-O;G1E;G1?5'EP97-=+GAM;*V334[#,!"% MKQ)E6R4N+%B@IAM@"UUP 6-/&JO^DV=:TMLS3MI*H!(5A4VL>-Z\SYZ7K-Z/ M$;#HG?78E!U1?!0"50=.8ATB>*ZT(3E)_)JV(DJUDUL0]\OE@U#!$WBJ*'N4 MZ]4SM')OJ7CI>1M-\$V9P&)9/(W"S&I*&:,U2A+7Q<'K'Y3J1*BY<]!@9R(N M6%"*JX1<^1UPZGL[0$I&0[&1B5ZE8Y7HK4 Z6L!ZVN+*&4/;&@4ZJ+WCEAIC M JFQ R!GZ]%T,4TFGC",S[O9_,%F"LC*30H1.;$$?\>=(\G=560C2&2FKW@A MLO7L^T%.6X.^D4NS6^X K M @ $0 @ &O 9&]C4')O<',O8V]R92YX;6Q02P$"% ,4 M " "IB3]6F5R<(Q & "<)P $P @ ', 0 >&PO=&AE M;64O=&AE;64Q+GAM;%!+ 0(4 Q0 ( *F)/U:'5DH3[P, $,/ 8 M " @0T( !X;"]W;W)K&PO&PO7W)E;',O M=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4 " "IB3]699!YDAD! #/ P M$P @ $\$@ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08 .."0 ) #X" "&$P ! end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.22.4 html 1 20 1 false 0 0 false 3 false false R1.htm 000001 - Document - Cover Sheet http://unitedhealthproductsinc.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ueec_8k.htm ueec-20230125.xsd ueec-20230125_cal.xml ueec-20230125_def.xml ueec-20230125_lab.xml ueec-20230125_pre.xml ueec_ex991.htm http://xbrl.sec.gov/dei/2022 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "ueec_8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 20 }, "contextCount": 1, "dts": { "calculationLink": { "local": [ "ueec-20230125_cal.xml" ] }, "definitionLink": { "local": [ "ueec-20230125_def.xml" ] }, "inline": { "local": [ "ueec_8k.htm" ] }, "labelLink": { "local": [ "ueec-20230125_lab.xml" ] }, "presentationLink": { "local": [ "ueec-20230125_pre.xml" ] }, "schema": { "local": [ "ueec-20230125.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd", "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd", "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd", "https://xbrl.sec.gov/country/2022/country-2022.xsd", "https://xbrl.sec.gov/currency/2022/currency-2022.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/exch/2022/exch-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd", "https://xbrl.sec.gov/sic/2022/sic-2022.xsd", "https://xbrl.sec.gov/stpr/2022/stpr-2022.xsd" ] } }, "elementCount": 21, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 20, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ueec", "nsuri": "http://unitedhealthproductsinc.com/20230125", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_8k.htm", "contextRef": "From2023-01-25to2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000001 - Document - Cover", "menuCat": "Cover", "order": "1", "role": "http://unitedhealthproductsinc.com/role/Cover", "shortName": "Cover", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "strong", "p", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "ueec_8k.htm", "contextRef": "From2023-01-25to2023-01-25", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address Address Line 1" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address Address Line 2" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address City Or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address State Or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://unitedhealthproductsinc.com/role/Cover" ], "xbrltype": "booleanItemType" } }, "unitCount": 3 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 16 0001477932-23-000656-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001477932-23-000656-xbrl.zip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end